Drug Profile
BI 905677
Alternative Names: BI-905677Latest Information Update: 17 Aug 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics
- Mechanism of Action Low density lipoprotein receptor related-protein-6-inhibitors; Low density lipoprotein receptor-related protein-5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Aug 2022 Phase I development in Solid tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA, Japan, the Netherlands, Spain (IV, Infusion) (NCT03604445)
- 27 Jul 2022 Boehringer Ingelheim terminates a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Spain, Netherlands, Japan and USA (IV) (NCT03604445)
- 08 Apr 2022 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research(AACR-2022)